The diversifier ousted by shareholders, and the KKR take-private (2026)

A chief his shareholders rejected, and where the take-private leads

At the heart of this whole contest is a manager who had led diversification for fifteen years being pushed out of his seat on the board by his own company’s shareholders, and, as an extension of that, the company itself heading toward going private. Even though the share price had risen several-fold during President Sato’s tenure, the major shareholders were not satisfied with its capital efficiency or with how control was arranged. Even a company with an unshakeable core business — the world’s top position in solder resist — can see its top seat overturned once the use of the cash it earns and the discipline of its management are called into question. This case hints that scenes in which shareholders’ voices sway the fate of management have begun to stand out among Japan’s listed companies.

The questions left open are not few. The tender-offer price was a discount below the market, the top shareholder and the founding family are exiting at a price lower still, and the head of the very pharmaceutical division that had drawn the criticism — the departed former president — stayed on. Under whose discipline is the leading maker of the solder resist that underpins the world’s printed circuit boards now to be raised? Whether the choice to entrust it to a new steward in KKR can reconcile the capital efficiency the shareholders demanded with the continuity of the businesses it has diversified into cannot be foreseen as of this writing. Whether the resolution of leaving the public market was the best one can be measured only after waiting out the several years that follow going private.